Session » (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0001

ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 0015

CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases

10:30AM-12:30PM: Abstract Number: 0008

Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform

10:30AM-12:30PM: Abstract Number: 0018

Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases

10:30AM-12:30PM: Abstract Number: 0013

Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases

10:30AM-12:30PM: Abstract Number: 0003

In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles

10:30AM-12:30PM: Abstract Number: 0002

KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0012

KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety

10:30AM-12:30PM: Abstract Number: 0011

KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release

10:30AM-12:30PM: Abstract Number: 0005

LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells

10:30AM-12:30PM: Abstract Number: 0009

MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model

10:30AM-12:30PM: Abstract Number: 0014

NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease

10:30AM-12:30PM: Abstract Number: 0006

QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0010

XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].